Early Use of Iloprost in Nonfreezing Cold Injury.


Journal

Wilderness & environmental medicine
ISSN: 1545-1534
Titre abrégé: Wilderness Environ Med
Pays: United States
ID NLM: 9505185

Informations de publication

Date de publication:
09 2022
Historique:
received: 06 12 2021
revised: 20 04 2022
accepted: 25 04 2022
pubmed: 16 7 2022
medline: 21 9 2022
entrez: 15 7 2022
Statut: ppublish

Résumé

Nonfreezing cold injury (NFCI) is caused by prolonged exposure to cold, usually wet conditions and represents a separate pathological entity from frostbite. The pathophysiology of NFCI is characterized by vasoconstriction and microcirculatory disturbance. Iloprost, a synthetic prostaglandin analogue with vasodilatory properties is a recognized adjuvant treatment in frostbite; however, its role in NFCI is unclear. We present a case of a 29-y-old man with severe NFCI to both forefeet after prolonged immersion in cold seawater. Initial treatment with passive rewarming, analgesia and aspirin was initiated. Infusion of iloprost was used within 24 h from presentation and was well tolerated. This resulted in reduced tissue loss compared to the apparent tissue damage documented during the initial assessment. Delayed surgical intervention allowed minor debridement and minor toe amputations, maintaining the patient's ability to ambulate. This case demonstrates the safe use of iloprost in acute NFCI and highlights the importance of delayed surgical intervention in patients presenting with severe NFCI.

Identifiants

pubmed: 35840449
pii: S1080-6032(22)00068-0
doi: 10.1016/j.wem.2022.04.009
pii:
doi:

Substances chimiques

Iloprost JED5K35YGL
Aspirin R16CO5Y76E

Types de publication

Case Reports

Langues

eng

Sous-ensembles de citation

IM

Pagination

344-347

Informations de copyright

Copyright © 2022 Wilderness Medical Society. Published by Elsevier Inc. All rights reserved.

Auteurs

Adam Tam (A)

Royal Cornwall Hospitals NHS Trust, United Kingdom. Electronic address: adam.tam1@nhs.net.

Thomas Lyons (T)

Royal Cornwall Hospitals NHS Trust, United Kingdom.

Sarath Vennam (S)

Royal Cornwall Hospitals NHS Trust, United Kingdom.

Rachel Barnes (R)

Royal Cornwall Hospitals NHS Trust, United Kingdom.

Christopher Imray (C)

University Hospitals Coventry and Warwickshire NHS Trust, United Kingdom.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH